Option chain shows key data for Cingulate's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cingulate.

Cingulate (NASDAQ:CING) Stock, Option Chain

Cingulate

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Meta Platforms

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CING

MSFT

TMUS

Meta Platforms To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday

wall-street-ai17

Broad U.S. Equity ETFs

Exclusives

Tech

ETFs

AAPL

AMZN

APDN

ASTS

CRWD

GOVX

INDO

LUMN

LUNR

NVDA

PLTR

SERV

SMCI

TSLA

VRAX

ZAPP

A look at the top 20 most-searched tickers on Benzinga Pro for the month of August.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?

Screenshot 2024-09-03 at 6.27.41 PM

Biotech

Interview

General

New ADHD Medication Is On Track For NDA Filing Within A Year – Hear From This Biotech&#39;s CEO

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

Legal

Press Releases

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Announces Adjournment of Special Meeting

Cingulate to Participate in Benzinga All Live Access Event

September 04, 2024 09:00 AM, Eastern

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Health Care

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Earnings

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Financing

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Final Study Completed for Cingulate's Lead Asset CTx-1301

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

CINGW

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Athira Pharma

Aytu BioPharma

Biofrontera

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cocrystal Pharma

China Pharma Holding

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

Jaguar Health

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Talphera

Traws Pharma

TherapeuticsMD

HC Wainwright & Co.

Roth MKM

Screenshot 2024-07-02 at 9.57.07 AM

This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment

Screenshot 2024-06-17 at 5.44.16 PM

Cingulate (NASDAQ: CING) Receives FDA Clearance To Apply For New ADHD Drug Approval

Screenshot 2024-05-07 at 10.50.27 PM

FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery